BCM
AVIR icon

Bluefin Capital Management’s Atea Pharmaceuticals AVIR Stock Holding History

Bluefin Capital Management’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-24,216
Closed -$70.2K – 191
2025
Q3 		$70.2K Buy
+24,216
New +$82.7K 0.02% 61

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bluefin Capital Management's AVIR Position: Q4 2025 in Review

Bluefin Capital Management sold out of Atea Pharmaceuticals (AVIR) in Q4 2025, closing a stake of 24,216 shares — an estimated $70.2K sold.

Bluefin Capital Management first reported a position in AVIR in Q3 2025 and held it in 1 quarter. The position peaked at $70.2K in Q3 2025. 111 funds tracked by Wall St. Rank hold AVIR as of Q4 2025.

  • Bluefin Capital Management reported no remaining Atea Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Bluefin Capital Management sold 24,216 Atea Pharmaceuticals shares in Q4 2025, an estimated $70.2K.
  • Bluefin Capital Management first reported a position in Atea Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Bluefin Capital Management's Atea Pharmaceuticals position peaked at $70.2K in Q3 2025.
  • 111 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q4 2025.

Based on Bluefin Capital Management's 13F filing for Q4 2025, filed 29 Apr 2026.